财经金融新闻 外资药业影响力下滑（在线收听）

Profit margins for multinational pharmaceutical companies in China are being met with big pains on expiring patents and policy changes. President of the Pharmaceutical Association Committee Zhuo Yongqing said foreign and domestic pharma companies are experiencing slower growth. And while international companies once saw surging profits in years past, a slew of challenges have resulted in a turning of the tides.

因“专利到期”和政策调整，中国的跨国医药公司效益惨淡。药品委员会主席卓永清认为，不管是外资公司还是国内医药公司，都出现了收益放缓现象。几年前，国外医药公司一团红火，但由于受到诸多挑战，现已大不如前。

Drug giants Bristol-Myers Squibb and GlaxoSmithKline have each laid off some 1,000 employees in the past few years, attributing the moves to changes in their business model. Meanwhile, dismissed employees have said the layoffs were due to profit declines. In February, Merck ended a joint venture with its Chinese partner, cutting some 300 jobs in China.

过去几年间，为了改变商业模式，药业巨头百时美施贵宝和葛兰素史克均裁员约1千人。与此同时，解聘员工称裁员是由于经济效益下滑。今年2月，默克集团结束了与一家中国公司的合资计划，裁减中国员工约300人。

Big Pharma has made large investments in China since 2010 to tap booming demand. But according to PharmAsia News, GSK reported a 3 percent decline in sales in China in the first quarter of this year. Eli Lilly and Co. reported 6 percent growth for first-quarter sales of this year, down 21 percent in 2014.

为了开发需求量，自2010年起，美国Big Pharma公司加大对中国投资力度。但根据“PharmAsia”新闻的报道，葛兰素史克今年第一季度销量减少了3%。美国礼来制药今年第一季度只增长了6%，2014年下降了21%。

Around the world, drug makers are also coming up against a clock running out on patents for some of their best-selling drugs. Foreign drug makers in China have also long contended with lengthy approval processes to enter the market. For new drugs to enter the market, a senior executive at a drug company said it takes five to eight years for registration and then another two years for the drug to appear in state drug procurement catalogs.

在全球，许多医药公司还要面对畅销药物的“专利悬崖”问题。由于投入市场的审批流程过长，许多外国公司还要为此进行长期斗争。为了让新药进入市场，一名公司高管称，新药注册需要五到八年，进入国家医保还需要两年。

For Caixin Online, this is Diana Bates.

这是戴安娜·贝茨为您带来的财新新闻报道。